Related Experiment Video

Updated: May 2, 2026

Oligopeptide Competition Assay for Phosphorylation Site Determination
09:16

Oligopeptide Competition Assay for Phosphorylation Site Determination

Published on: May 18, 2017

7.8K

The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth

Hyunjoo Kim1, Ho-June Lee2, Yumin Oh3

  • 11] School of Biological Science/Bio-Max Institute, Seoul National University, Gwanak-gu, Seoul 151-747, Korea [2].

Nature Communications
|February 20, 2014
PubMed

Insights

Adenylate kinase 2 (AK2) suppresses tumor growth by activating DUSP26 phosphatase. This complex dephosphorylates FADD, inhibiting cell proliferation and tumor formation. AK2 is a key negative regulator of cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Adenylate kinase 2 (AK2) is crucial for maintaining adenine nucleotide pools.
  • AK2 is recognized as a multi-functional protein with roles beyond nucleotide metabolism.

Purpose of the Study:

  • To investigate the role of Adenylate kinase 2 (AK2) in regulating tumor cell growth.
  • To elucidate the mechanism by which AK2 influences cell proliferation and tumorigenesis.

Main Methods:

  • Investigated the interaction between AK2 and dual-specificity phosphatase 26 (DUSP26).
  • Assessed the effect of AK2/DUSP26 complex on FADD dephosphorylation.
  • Utilized xenograft assays and mouse embryo fibroblasts to study AK2's function in vivo and in vitro.

Main Results:

  • AK2 forms a complex with DUSP26, enhancing its phosphatase activity.
  • The AK2/DUSP26 complex dephosphorylates FADD (fas-associated protein with death domain), suppressing cell proliferation.
  • AK2 deficiency leads to increased cell proliferation, tumor formation, and elevated phospho-FADD levels.
  • Downregulation of AK2 correlates with tumor progression and high phospho-FADD levels in human cancers.

Conclusions:

  • AK2 acts as a negative regulator of tumor growth by stimulating DUSP26 activity.
  • AK2-mediated FADD dephosphorylation is a key mechanism suppressing tumor cell proliferation and tumorigenesis.
  • AK2 represents a potential therapeutic target for cancer treatment.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K
Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development09:32

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

8.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K